Skip to main content

Table 5 All-cause and rheumatoid arthritis-related healthcare costs during 1-year follow-up

From: Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis

Healthcare costsa per patient Responders (n = 2337) Nonresponders (n = 2337) p Valueb
Mean (SD) Median (range) Mean (SD) Median (range)
Medical, all-cause
 Total medical 7581 (15,575) 2123 (0 – 301,318) 13,318 (23,433) 4238 (0 – 337,588) <0.001
 Inpatient hospitalizations 1509 (9,676) 0 (0 – 239,362) 3264 (14,549) 0 (0 – 314,893) <0.001
 Joint replacement surgeries 338 (3415) 0 (0 - 77,382) 656 (5403) 0 (0 - 102,929) 0.016
 Infections 149 (2154) 0 (0 - 81,742) 826 (7412) 0 (0 - 225,407) <0.001
 CV events 277 (6198) 0 (0 - 239,362) 464 (6482) 0 (0 - 211,055) 0.312
 ED encounters 207 (962) 0 (0 – 16,039) 460 (1909) 0 (0 – 40,264) <0.001
 Outpatient visits 5863 (10,666) 1922 (0 – 148,294) 9565 (15,840) 3460 (0 – 252,428) <0.001
 Physician office visits 1066 (877) 863 (0 – 15,573) 1424 (1237) 1118 (0 – 13,152) <0.001
 Rheumatologist office visits 304 (342) 221 (0 – 3715) 357 (455) 232 (0 – 4284) <0.001
 Physical/occupational therapy 131 (534) 0 (0 - 7567) 222 (851) 0 (0 - 14,319) <0.001
 DME 393 (10,188) 0 (0 - 484,558) 486 (4609) 0 (0 - 122,724) 0.686
 Imagingc 930 (2596) 210 (0 – 46,467) 1559 (3971) 350 (0 – 48,412) <0.001
Pharmacy, all-cause (excluding biologics) 1698 (2728) 903 (0 – 22,905) 2052 (3370) 1004 (0 – 41,748) <0.001
Total, all-cause (medical plus pharmacy, excluding biologics) 9278 (16,142) 3919 (0 – 306,913) 15,370 (24,447) 6599 (0 – 348,118) <0.001
Medical, RA-related 4498 (11,150) 590 (0 - 141,903) 7845 (16,300) 889 (0 - 282,902) <0.001
Pharmacy, RA-related 21,852 (9572) 23,042 (0 – 77,237) 13,273 (10,131) 12,445 (0 – 59,331) <0.001
 csDMARDs 214 (376) 87 (0 – 6992) 181 (360) 64 (0 – 6649) 0.002
 Biologics 21,808 (9719) 22,979 (0 – 77,220) 13,193 (10,212) 12,337 (0 – 68,752) <0.001
Total, RA-related (medical and pharmacy) 26,350 (10,196) 24,668 (191 – 142,091) 21,118 (16,725) 18,716 (0 – 285,900) <0.001
Total, all-cause (medical plus pharmacy, including biologics) 31,087 (15,556) 28,268 (2017 - 332,724) 28,563 (24,600) 23,701 (0 - 350,986) <0.001
  1. Abbreviations: csDMARD Conventional synthetic disease-modifying antirheumatic drug, CV Cardiovascular, DME Durable medical equipment, ED Emergency department, RA Rheumatoid arthritis
  2. a Plan-paid costs in 2014 U.S. dollars, assessed over the first year postindex
  3. b χ2 tests were used to determine statistical differences across categorical variables; t tests were used for continuous variables. In addition, a nonparametric bootstrap was used to calculate a second set of p values for comparisons of key mean cost metrics; these p values were similar to the ones derived from the t tests. The table therefore reports the t test p values
  4. c Imaging included radiographs, magnetic resonance imaging, and other types of imaging